Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

Sponsor
Peking University First Hospital
Study ID
NCT07000630
Status
Terminated

Conditions

  • Palmoplantar Pustulosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.

Study Details

The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.

Key Dates

Start date
Jun 20, 2025
Status verified
Mar 2026
Primary completion
Nov 30, 2025
Completion
Dec 1, 2025

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib treatment
    25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.

Primary Outcome Measure

Primary efficacy endpoint [ Time Frame: From enrollment to the end of treatment at 16 weeks ]

Related Studies